EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

Enrica Antonia Martino, Francesca Romana Mauro iD, Gianluigi Reda, Luca Laurenti iD, Andrea Visentin iD, Annamaria Frustaci iD, Ernesto Vigna, Sara Pepe, Gioacchino Catania, Giacomo Loseto, Roberta Murru, Annalisa Chiarenza and 16 more

Hematological Oncology · 2024

DOI: 10.1002/hon.3249 ↗

At a glance

Multizentrische Studie in Hematological Oncology, 2024. Written by Enrica Antonia Martino and 27 co-authors. Institution: Hematology Unit, AO Cosenza, Cosenza, Italy. Major MEDLINE topics: Adenine, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines. Cited 7 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Associazione Italiana Ricerca Cancro, Associazione Italiana contro le Leucemie, linfomi e mielomi, Venezia Section, Italy, Progetto Ricerca Finalizzata PNRR-MAD-2022-12375673.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Although chronic lymphocytic leukemia (CLL) predominantly affects the elderly, limited data exists about the outcomes of over 80‐year‐old patients, usually underrepresented in clinical trials. We conducted a multicenter study enrolling 79 consecutive CLL patients ≥80 years at the time of frontline therapy, all treated with ibrutinib. Nearly 48% of cases exhibited unmutated IGHV genes, 32% 17p deletion, and 39.2% TP53 mutations; 63.3% displayed a cumulative illness rating scale (CIRS) > 6. The overall response rate on ibrutinib, computed in 74/79 patients (5 patients excluded for early withdrawal), was 89.9%. After a median follow‐up of 28.9 months, the median progression‐free survival (PFS) and overall survival (OS) were 42.5 and 51.8 months, respectively. CIRS>6 and temporary discontinuation of ibrutinib lasting for 7–30 days were the only parameters associated with a significantly shorter PFS and were both relevant in predicting a shorter PFS compared to patients with CIRS≤6 and therapy discontinuation ≤7 days. The most common grade≥3 adverse events were infections (25.5%), neutropenia (10.1%), and anemia (2.5%). Eighteen patients (22.8%) experienced a cardiovascular event, including grade‐2 atrial fibrillation ( n = 9; 11%), grade‐2 hypertension ( n = 5; 6%), heart failure ( n = 3; 3%), and acute coronary syndrome ( n = 1; 1%). Mild bleeding events were observed in 27 patients (34.2%). Ibrutinib was permanently discontinued in 26 patients due to progressive disease ( n = 11, including 5 Richter's syndromes), secondary malignancies ( n = 6), infections ( n = 3), cardiac failure ( n = 3), severe bleeding ( n = 2), and sudden death ( n = 1). In conclusion, our analyses confirmed the overall effectiveness and favorable safety profile of the ibrutinib‐single agent therapeutic approach in CLL patients ≥80 years.

Subjects

MeSH terms (MEDLINE)

AdenineLeukemia, Lymphocytic, Chronic, B-CellPiperidinesAged, 80 and overHumansItalyRetrospective StudiesTreatment Outcome

Author keywords

chronic lymphocytic leukemiaelderlyibrutinibtherapy

Substances

AdenineibrutinibPiperidines

Authors and institutions

  • Hematology Unit, AO Cosenza, Cosenza, Italy.
  • Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
  • Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Dipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Rome, Italy.
  • Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

ORCID profiles: Francesca Romana Mauro, Luca Laurenti, Andrea Visentin, Annamaria Frustaci, Antonella Zucchetto, Alessandra Tedeschi, Davide Rossi, Livio Trentin, Massimo Gentile

Funding

  • Associazione Italiana Ricerca Cancro
  • Associazione Italiana contro le Leucemie, linfomi e mielomi, Venezia Section, Italy
  • Progetto Ricerca Finalizzata PNRR-MAD-2022-12375673
  • Italian Ministry of Health, Rome, Italy

Cite

APA

Martino, E. A., Mauro, F. R., Reda, G., Laurenti, L., Visentin, A., Frustaci, A., Vigna, E., Pepe, S., Catania, G., Loseto, G., Murru, R., Chiarenza, A., Sportoletti, P., Del Principe, M. I., Laureana, R., Coscia, M., Galimberti, S., Ferretti, E., Zucchetto, A., …, & Gentile, M. (2024). Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort. Hematological Oncology. https://doi.org/10.1002/hon.3249

Vancouver

Martino EA, Mauro FR, Reda G, Laurenti L, Visentin A, Frustaci A, et al. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort. Hematological Oncology. 2024. doi:10.1002/hon.3249

BibTeX
@article{Martino2024,
  author = {Martino, Enrica Antonia and Mauro, Francesca Romana and Reda, Gianluigi and Laurenti, Luca and Visentin, Andrea and Frustaci, Annamaria and Vigna, Ernesto and Pepe, Sara and Catania, Gioacchino and Loseto, Giacomo and Murru, Roberta and Chiarenza, Annalisa and Sportoletti, Paolo and Del Principe, Maria Ilaria and Laureana, Roberta and Coscia, Marta and Galimberti, Sara and Ferretti, Eleonora and Zucchetto, Antonella and Bomben, Riccardo and Polesel, Jerry and Tedeschi, Alessandra and Rossi, Davide and Trentin, Livio and Neri, Antonino and Morabito, Fortunato and Gattei, Valter and Gentile, Massimo},
  title = {Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3249}
}
Start for free →